Shanghai Kechow Pharma, Inc.
13
4
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.4%
2 terminated/withdrawn out of 13 trials
50.0%
-36.6% vs industry average
15%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Role: lead
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
Role: collaborator
Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects
Role: lead
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Role: lead
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
Role: lead
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Role: lead
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
Role: lead
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Role: lead
Study of HL-085 in NRAS Mutant Advanced Melanoma
Role: lead
HL-085 in NRAS-mutated Advanced Melanoma
Role: lead
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Role: lead
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Role: lead
Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Role: lead
All 13 trials loaded